Effect of intraoperative intravenous lidocaine on pain and plasma interleukin-6 in patients undergoing hysterectomy  by de Oliveira, Caio Marcio Barros et al.
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Abstract
Background  and  objectives:  Interleukin-6  is  a  predictor  of  trauma  severity.  The  purpose  of
this study  was  to  evaluate  the  effect  of  intravenous  lidocaine  on  pain  severity  and  plasma
interleukin-6  after  hysterectomy.
Method:  A  prospective,  randomized,  comparative,  double-blind  study  with  40  patients,  aged
18--60 years.  G1  received  lidocaine  (2  mg  kg−1 h−1)  or  G2  received  0.9%  saline  solution  during
the operation.  Anesthesia  was  induced  with  O2/isoﬂurane.  Pain  severity  (T0:  awake  and  6,  12,
18 and  24  h),  ﬁrst  analgesic  request,  and  dose  of  morphine  in  24  h  were  evaluated.  Interleukin-6
was measured  before  starting  surgery  (T0),  5  h  after  the  start  (T5),  and  24  h  after  the  end  of
surgery (T24).
Results:  There  was  no  difference  in  pain  severity  between  groups.  There  was  a  decrease  in
pain severity  between  T0  and  other  measurement  times  in  G1.  Time  to  ﬁrst  supplementation
was greater  in  G2  (76.0  ±  104.4  min)  than  in  G1  (26.7  ±  23.3  min).  There  was  no  difference  in
supplemental  dose  of  morphine  between  G1  (23.5  ±  12.6  mg)  and  G2  (18.7  ±  11.3  mg).  There
were increased  concentrations  of  IL-6  in  both  groups  from  T0  to  T5  and  T24.  There  was  no
difference  in  IL-6  dosage  between  groups.  Lidocaine  concentration  was  856.5  ±  364.1  ng  mL−1
in  T5  and  30.1  ±  14.2  ng  mL−1 in  T24.
 Study performed at the Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil.
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Conclusion:  Intravenous  lidocaine  (2  mg  kg−1 h−1)  did  not  reduce  pain  severity  and  plasma  levels
of IL-6  in  patients  undergoing  abdominal  hysterectomy.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  All  rights
reserved.
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Lidocaína;
Via  venosa;
Dor  pós-operatória;
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Interleucina-6
Efeito  da  lidocaína  venosa  intraoperatória  sobre  dor  e  interleucina-6  plasmática  em
pacientes  submetidas  a  histerectomia
Resumo
Justiﬁcativa  e  objetivos:  A  interleucina-6  (IL-6)  é  preditora  de  intensidade  no  trauma.  O  obje-
tivo deste  estudo  foi  avaliar  o  efeito  da  lidocaína  por  via  venosa  sobre  a  intensidade  da  dor  e
IL-6 após  histerectomia.
Método:  O  estudo  foi  prospectivo,  randomizado,  comparativo  e  duplo-encoberto  em  40
pacientes, entre  18  e  60  anos.  Foi  administrada  lidocaína  (2  mg.kg−1.h−1)  no  G1  ou  soluc¸ão
salina a  0,9%  no  G2  durante  a  operac¸ão.  A  anestesia  foi  com  O2/isoﬂurano.  Foi  avaliada  a
intensidade  da  dor  (T0:  despertar  e  seis,  12,  18  e  24  horas),  a  primeira  solicitac¸ão  de  anal-
gésico, a  dose  de  morﬁna  nas  24  horas.  A  IL-6  foi  medida  antes  do  início  da  operac¸ão  (T0),  após
cinco horas  do  início  (T5)  e  24  horas  após  o  término  (T24).
Resultados:  Não  houve  diferenc¸a  na  intensidade  da  dor  entre  os  grupos.  Ocorreu  diminuic¸ão
da intensidade  da  dor  entre  T0  e  os  outros  momentos  avaliados  no  G1.  O  tempo  para  primeira
complementac¸ão foi  maior  no  G2  (76,0  ±  104,4  min)  do  que  no  G1  (26,7  ±  23,3  min).  Não  houve
diferenc¸a na  dose  de  morﬁna  complementar  entre  G1  (23,5  ±  12,6  mg)  e  G2  (18,7  ±  11,3  mg).
Houve aumento  das  concentrac¸ões  de  IL-6  em  ambos  os  grupos  de  T0  para  T5  e  T24.  Não  houve
diferenc¸a na  dosagem  de  IL-6  entre  os  grupos.  A  concentrac¸ão  de  lidocaína  foi  856,5  ±  364,1
ng.mL−1 em  T5  e  30,1  ±  14,2  ng.mL−1 em  T24.
Conclusão:  A  lidocaína  (2  mg.kg−1.h−1)  por  via  venosa  não  promoveu  reduc¸ão  da  intensidade
da dor  e  dos  níveis  plasmáticos  de  IL-6  em  pacientes  submetidas  a  histerectomia  abdominal.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
direitos reservados.
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Both  the  dose  and  duration  of  lidocaine  infusion  remain
controversial.  Moreover,  its  effectiveness  has  not  yet
been  determined.  Surgical  trauma  results  in  the  release
of  cytokines  that  are  responsible  for  local  inﬂammatory
responses  and  promote  tissue  healing.1 Interleukin-6  (IL-6)  is
a  cytokine  that  is  early  detected  in  response  to  injury  and  its
increase  is  correlated  with  the  degree  of  tissue  damage.1,2
Some  authors  have  reported  that  intravenous  lidocaine
promotes  reduction  of  cytokines,3,4 inhaled  anesthetics5 and
opioids  consumption,6,7 and  postoperative  pain  severity.3,6,7
Furthermore,  low  doses  of  intravenous  lidocaine  (plasma
concentrations  less  than  5  g  mL−1)  do  not  interfere  with
normal  nerve  conduction  and  are  associated  with  a  lower
incidence  of  opioid-related  adverse  effects.3,6,8
Lidocaine  has  analgesic,6 anti-hyperalgesic,6,9 and  anti-
inﬂammatory  effects.4,10 Analgesia  may  persist  even  after
plasma  concentration  reduction.10,11
The  voltage-gated  sodium  channels  are  the  classic  tar-
gets  of  lidocaine.12 The  analgesic  and  anti-inﬂammatory
action  also  occurs  through  calcium  and  potassium  chan-
nels  and  receptors  coupled  to  G  protein.13,14 The  neuronal
transmission  blockade  and  reduced  neurogenic  response  are
d
d
c
taused  by  the  action  on  sodium  and  potassium  channels.13,15
idocaine  metabolite,  monoethylglycinexylidide  (MEGX),
ay  also  exert  analgesic  effect.16 Unlike  MEGX,  lido-
aine  reduces  glycine  uptake  only  at  toxic  concentrations.
owever,  other  studies  reported  no  analgesic  effect  of
idocaine.17,18
Thus,  the  primary  objective  of  this  study  was  to  eval-
ate  the  effect  of  intraoperative  intravenous  lidocaine  on
ostoperative  pain  severity  and  plasma  levels  of  IL-6  after
bdominal  hysterectomy.
ethods
fter  approval  by  the  Research  Ethics  Committee  of  the  Fed-
ral  University  of  São  Paulo  and  obtaining  written  informed
onsent,  40  patients,  ASA  1  or  2,  aged  between  18  and  60
ears,  undergoing  elective  total  hysterectomy  by  laparo-
omy  through  a  Pfannenstiel  incision  were  included.
Patients  who  experienced  cardiac  arrhythmia;  car-
iomyopathy;  cardiac  conduction  abnormality;  electrolyte
isorders;  acid--base  imbalance;  hypersensitivity  to  lido-
aine;  psychiatric,  hepatic,  respiratory  or  cancer  disease;
hose  receiving  any  type  of  painkiller  in  the  week  before
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urgery  or  received  blood  products  during  the  study  period
ere  excluded.
This  was  a  prospective,  double  blind  and  randomized
tudy.  Patients  were  randomly  allocated  into  two  groups  of
qual  size  by  lot  to  receive  either  lidocaine  infusion  (G1)
r  0.9%  saline  infusion  (G2/control).  Randomization  was
erformed  using  G1  and  G2  registers,  which  were  placed
n  sealed  envelopes  prior  to  study  initiation  and  opened
pproximately  30  min  prior  to  anesthesia  by  a  physician  who
repared  the  intravenous  solution  and  identiﬁed  it  with  the
atient  number,  according  to  the  envelope  drawn.  The  solu-
ion  was  handed  to  another  physician,  blind  to  the  prepared
olutions’  content,  who  was  responsible  for  the  anesthesia.
he  solution  volume  was  equal.  The  responsible  investiga-
or  remained  blind  to  the  chosen  group  until  the  end  of  the
tudy.
G1  patients  (n  =  20)  received  2  mg  kg−1 h−1 of  lidocaine
nd  G2  patients  (n  =  20)  received  an  equal  volume  of  0.9%
aline,  whose  infusion  was  initiated  at  the  time  of  induction
f  anesthesia  and  continued  until  the  end  of  the  operation.
Midazolam  was  administered  at  a  dose  of  15  mg  orally  1  h
efore  anesthesia.  Patients  were  monitored  with  continuous
lectrocardiography  and  pulse  oximetry  and  intermittent
oninvasive  blood  pressure  measurements  every  5  min.
nduction  of  anesthesia  was  performed  with  fentanyl
5  g  kg−1)  and  propofol  (2  mg  kg−1);  neuromuscular  block-
de  was  achieved  with  atracurium  (0.5  mg  kg−1).  Anesthesia
as  maintained  with  O2/isoﬂurane  at  sufﬁcient  dose  to
aintain  systolic  blood  pressure  within  the  limit  of  20%  base-
ine  value.  Neuromuscular  blockade  was  maintained  with
tracurium  (0.2  mg  kg−1)  administered  every  30  min.  During
urgery,  additional  doses  of  opioids  or  other  analgesics  were
ot  used.  There  was  no  prophylaxis  for  postoperative  nausea
nd  vomiting.
After  surgery,  patients  were  monitored  in  the  recovery
oom  and  later  taken  to  the  ward.  Morphine  (5  mg)  was
dministered  subcutaneously  using  a  23  G  scalp,  as  neces-
ary.
Blood  samples  were  collected  in  ethylene  diamine  tetra
cetate  (EDTA)  tubes  immediately  after  contralateral  upper
imb  venipuncture,  before  the  operation  (T0),  5  h  after  the
tart  of  surgery  (T5),  and  24  h  after  surgery  (T24).  Blood  sam-
les  were  centrifuged  and  plasma  was  separated  and  stored
t  −70 ◦C  up  to  analysis.  The  levels  of  IL-6  were  analyzed
sing  the  enzyme-linked  immunoassay  (ELISA).  Lidocaine
nd  its  metabolite  MEGX  were  analyzed  using  high  perfor-
ance  liquid  chromatography  (HPLC)  5  h  after  the  start  of
urgery  and  24  h  after  surgery.
Pain  severity  was  assessed  at  rest  using  a  verbal  numeric
cale  (VNS)  from  zero  to  10  (where  0  =  no  pain  and  10  =  most
evere  pain  possible).  A  verbal  descriptive  scale  (VDS)  was
lso  used:  0  =  no  pain,  1  =  mild  pain,  2  =  moderate  pain,
nd  3  =  severe  pain.  The  scores  were  recorded  at  the
ollowing  times:  T0  =  immediately  at  awakening;  T6  =  6  h
fter  awakening;  T12  =  12  h  after  awakening;  T18  =  18  h  after
wakening;  T24  =  24  h  after  awakening.
For  postoperative  analgesia,  morphine  (5  mg)  was  sub-
utaneously  administered  by  a  nurse,  as  needed.  The  ﬁrst
nalgesic  request,  the  supplemental  dose  of  morphine  nec-
ssary  for  the  ﬁrst  24  h,  and  the  dose  of  isoﬂurane  used
ntraoperatively  were  recorded;  side  effects  were  also
ecorded.
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tatistical  analysis
ample  size  calculation  was  performed  with
raphPadInstat® program  (GraphPad  Software  Inc.,  San
iego,  CA,  USA).  For  such,  we  considered  the  reduction
f  pain  severity  caused  by  lidocaine.  Based  on  a  pilot
tudy  conducted  by  the  same  research  group,  the  standard
eviation  (SD)  was  estimated  at  2.2.  A  difference  of  at  least
 in  VNS  (0--10)  was  considered  clinically  relevant.  Because
ain  is  subjective  and  individual,  three  levels  of  difference
ere  considered  a  signiﬁcant  pattern  of  change  or  an
mprovement  factor  or  a  signiﬁcant  worsening.  Conﬁdence
nterval  was  95%.  Thus,  a  sample  with  a minimum  of  20
atients  per  group  was  calculated.  The  following  tests  were
sed:  Mann--Whitney  test  to  compare  age  and  body  mass
ndex  (BMI);  Student  t-test  to  compare  weight,  height,
uration  of  anesthesia,  duration  of  surgery,  time  to  ﬁrst
nalgesic  supplementation,  total  morphine  consumption  in
4  h,  pain  intensity,  total  isoﬂurane  consumption,  and  IL-6
lasma  levels.  Data  were  expressed  as  mean  ±  SD.
esults
ig.  1  shows  the  study  ﬂowchart.19 The  groups  were  simi-
ar  regarding  demographic  data  and  duration  of  surgery  and
nesthesia  (Table  1).
There  was  no  difference  between  the  two  groups  in  the
ime  points  evaluated  (Table  2).  There  was  no  statistically
igniﬁcant  difference  in  IL-6  concentration  between  groups
Table  3).
The  postoperative  time  to  ﬁrst  morphine  dose  request
or  analgesia  was  higher  in  G2  (76  ±  104.4)  than  in  G1
26.7  ±  23.3)  (Table  4).  There  was  no  difference  between
roups  regarding  supplementary  morphine  dose  and  volume
f  isoﬂurane  (Table  4).  Table  5  shows  the  concentrations
f  lidocaine  and  its  metabolite,  MEGX.  Nausea  occurred  in
even  patients  in  each  group.
iscussion
here  was  no  analgesic  effect  with  intravenous  lidocaine
nfusion  and  also  no  reduction  in  plasma  concentration  of
L-6.
In  this  study,  the  open  hysterectomy  was  chosen  because
t  is  associated  with  severe  postoperative  pain,  with  a
reat  chance  of  changes  in  the  neuronal  processing  of  the
pinal  dorsal  horn,  which  would  allow  us  to  compare  the
roups.20
Previous  studies  have  used  larger  doses  of  lidocaine  for
ntravenous  infusion  and  some  used  initial  bolus,  which  may
xplain  the  lack  of  analgesic  effect  in  this  study.3,5--7
In  one  study,3 lidocaine  (2  mg  kg−1)  was  administered  as
 bolus  and  maintained  with  infusion  of  3  mg  kg−1 h−1.  In
nother  study,6 the  analgesic  and  sparing  effect  of  morphine
as  most  evident  on  the  third  postoperative  day,  but  this
tudy  was  limited  to  24  h.
It  must  be  remembered  that  the  dose  and  duration  of
idocaine  venous  infusion,  with  the  objective  of  obtaining
ostoperative  analgesia,  have  not  been  well  deﬁned.21 How-
ver,  some  studies  have  reported  good  results  with  low  doses
f  lidocaine  (plasma  concentrations  less  than  5  g  mL−1).6
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Figure  1  Flowchart  based  on  Consort.19
Table  1  Demographic  data,  operation  and  anesthesia  times.
G1  G2  p
Age  (years)  44.1  ±  6.6  42.9  ±  5.7  0.646a
Weight  (kg)  72.2  ±  13.7  74.2  ±  12.6  0.379b
Height  (cm)  159.12  ±  6.5  158.0  ±  6.6  0.343b
BMI  (kg  m−2) 28.5  ±  5.4  29.7  ±  5.3  0.133a
Operation  time  (min) 102.6  ±  49.4 93.0  ±  48.2  0.122b
Anesthesia  time  (min) 145.1  ±  51.8  124.0  ±  43.8  0.172b
G1, lidocaine; G2, saline solution; BMI, body mass index.
a Mann--Whitney test.
b Student’s t-test.
Table  2  Pain  intensity  by  numerical  rating  scale.
Times  (h)  G1  (n  =  20)  G2  (n  =  20)  p
Scores  IC  95%  Scores  CI  95%
T0  3.2  ±  3.9  1.3--5  2.5  ±  3.7  0.7--4.2  0.602
T6 1.4  ±  1.8  0.5--2.3  1.8  ±  1.6  1--2.5  0.307
T12 0.8  ±  1.5  0--1.4  1.3  ±  1.8  0.4--2.1  0.307
T18 0.9  ±  1.5  0.1--1.5  1  ±  1  0.5--1.5  0.476
T24 1  ±  1.6  0.3--1.8  1.3  ±  1.6  0.5--2  0.602
G1, lidocaine; G2, saline solution; CI 95%, 95% conﬁdence interval; T0, awakening; T6, T12, T18 and T24, 6, 12, 18 and 24 h after
awakening.Because  the  measurement  of  plasma  lidocaine  was  not
part  of  the  purpose  of  this  study  and  served  only  as  addi-
tional  information,  its  analysis  was  made  at  the  same  dosage
times  of  IL-6:  before  beginning  surgery  (T0),  5  h  after  the
s
s
2
etart  of  surgery  (T5)  and  24  h  after  the  end  of  anesthe-
ia  (T24).  As  the  longest  surgery  time  in  G1  lasted  up  to
10  min,  blood  sample  was  not  collected  during  the  intraop-
rative  infusion  of  lidocaine.  Therefore,  it  was  not  possible
96  C.M.B.  Oliveira  et  al.
Table  3  Plasma  concentration  of  IL-6  (pcg  mL−1).
Times  (h)  G1  (n  =  20)  G2  (n  =  20)  p
T0  0.95  ±  4.25  2.56  ±  7.55  0.602
T5 20.34  ±  17.83  19.44  ±  17.88  0.841
T24 24.95  ±  14.82  34.73  ±  15.62  0.056
G1, lidocaine; G2, saline solution; T0, before surgical incision; T5, 5 h after the incision; T24, 24 h after skin suture.
Table  4  Volume  of  isoﬂurane  used,  time  to  ﬁrst  analgesic  request,  and  additional  analgesic  dose  of  morphine  over  24  h
(mean ±  SD).
G1  (n  =  20)  G2  (n  =  20)  p
Time  to  ﬁrst  supplementation  (min)  26.7  ±  23.3  76.0  ±  104.4  0.046
Additional dose  of  morphine  in  24  h  (mg)  23.5  ±  12.6  18.7  ±  11.3  0.217
Volume of  isoﬂurane  used  (mL)  25.2  ±  8.9  26.5  ±  10.6  0.679
t
T
a
c
t
n
s
a
h
t
u
s
I
o
b
b
i
t
t
t
g
r
c
i
m
a
p
b
(
t
i
4
i
t
f
e
t
s
I
i
M
o
e
i
l
r
1
c
o
s
b
cG1, lidocaine; G2, saline solution; Student’s t-test.
o  measure  the  peak  concentration  of  lidocaine.  At  T5  and
24,  the  measurement  of  lidocaine  averaged  0.86  g  mL−1
nd  0.55  g  mL−1,  respectively.  These  results  are  well  below
oncentrations  considered  effective,  which  range  from  2
o  10  g  mL−1.22 In  this  study,  intravenous  lidocaine  did
ot  reduce  postoperative  pain  severity,  similar  to  some
tudies,16--18 probably  because  of  the  short  infusion  time  and
bsence  of  initial  bolus  dose.
Although  it  has  been  reported  that  there  would  be  a
igher  analgesic  effect  that  would  increase  the  infusion
ime,  instead  of  lidocaine  dose,  the  study  of  Koppert  et  al.,6
sing  low  dose  infusion  of  lidocaine  for  up  to  1  h  after
urgery,  showed  positive  prolonged  results  for  up  to  72  h.
n  our  study,  lidocaine  infusion  was  discontinued  at  the  end
f  surgery,  as  in  other  studies.3,5,8,23-26 Lidocaine  dose  was
ased  on  the  study  by  Lauwick  et  al.5 Indeed,  lidocaine
olus  was  not  used  before  infusion  because  in  some  stud-
es  there  was  a  reduction  in  postoperative  pain  with  only
he  infusion.23,27
In  this  study,  patients  who  received  lidocaine  required
heir  ﬁrst  analgesic  supplementation  earlier  than  the  con-
rol  group.  One  possible  explanation  for  this  result  may  be  a
reat  individual  variability  in  pain  thresholds  and  patients’
esponse  to  analgesics.  Because  there  was  considerable  dis-
repancy  in  the  ﬁrst  analgesic  request  time  among  patients
n  G2,  the  group  standard  deviation  was  greater  than  the
ean.
Interleukin-6  (IL-6)  is  an  early  marker  of  tissue  damage
nd  its  excessive  and  prolonged  increase  is  related  to  greater
ostoperative  morbidity.2 In  our  study,  IL-6  was  measured
efore  the  start  of  surgery  (T0),  5  h  from  the  start  of  surgery
Table  5  Plasma  levels  of  lidocaine  and  monoethyl-
glycinexylidide  (MEGX)  (ng  mL−1)  in  G1.
Times  (h)  Lidocaine  MEGX
T5  856.5  ±  364.1  545.6  ±  212.9
T24 30.1  ±  14.2  ND
G1, lidocaine; T5, 5 h after the incision; T24, 24 h after skin
suture; ND, not detectable.
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vT5),  and  24  h  after  the  end  of  anesthesia  (T24),  according
o  the  plasma  peak  described  in  the  work  by  Hong  et  al.,28
n  which  IL-6  is  detected  in  60  min  with  blood  peak  between
 and  6  h  and  may  persist  for  10  days.
There  was  a  statistically  signiﬁcant  progressive  increase
n  IL-6  dosage  in  each  group.  The  highest  value  was  at
he  last  collection  time  (24  h  after  surgical  suture).  This
act  contrasts  with  the  works  by  Lin  et  al.1 and  Herroeder
t  al.,4 with  IL-6  peak  between  4  and  6  h  in  the  postopera-
ive  period,  and  Kuo  et  al.,3 with  IL-6  peak  10  and  12  h  after
urgery.  There  was  an  increasing  trend  in  the  last  dose  of
L-6  in  G2  compared  to  G1,  which  shows  a  possible  anti-
nﬂammatory  effect  of  lidocaine  or  its  active  metabolite,
EGX,  even  after  the  end  of  infusion  and  beyond  the  half-life
f  elimination.  Probably,  a  statistically  signiﬁcant  differ-
nce  would  be  shown  between  groups  if  the  sample  size  was
ncreased.
Experimental  studies  have  shown  that  MEGX,  but  not
idocaine,  increased  the  glycinergic  activity  (inhibitory  neu-
otransmission)  through  GlyT1blockade  (glycine  transporter-
)  in  central  nervous  system  in  clinically  relevant
oncentrations.16,29,30 In  our  study,  the  mean  concentration
f  MEGX  reached  was  0.55  g  mL−1 5  h  after  the  start  of
urgery,  similar  to  the  level  which  leads  to  the  in  vitro  inhi-
ition  of  glycine  transport,  which  was  observed  during  the
ontinuous  infusion  of  lidocaine.29
Unlike  some  previous  studies,6,7 lidocaine  showed  no
soﬂurane  and  morphine-sparing  effect  in  our  study.  Fur-
hermore,  there  was  no  difference  in  total  morphine
onsumption  between  groups.  Similarly,  some  studies  have
eported  analgesic  effect  with  lidocaine.17,18 It  is  possible
hat  these  ﬁndings  are  related  to  unique  patterns  of  periph-
ral  and  central  sensitization  that  vary  with  the  different
ype  and  location  of  surgeries.23
The  analgesic  effects  of  lidocaine  are  more  pronounced
hen  it  is  infused  intraoperatively6 and  may  continue  for
ays  or  weeks,  that  is,  beyond  infusion  time  and  plasma
alf-life,11,31 indicating  its  action  on  other  targets,  not
nly  the  voltage-gated  sodium  channels,  and  suggesting  a
ypersensitivity  prevention  of  the  central  or  peripheral  ner-
ous  system,  or  both.7 In  abdominal  surgery,  lidocaine  has
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decreased  the  duration  of  paralytic  ileus,  postoperative  pain
severity,  and  opioid  consumption.32--34
A  clinically  signiﬁcant  reduction  in  pain  severity  was
observed  in  the  awakening  time  in  relation  to  other  mea-
sured  time  with  lidocaine,  but  not  in  G2,  which  may  reﬂect
the  beneﬁcial  effect  of  lidocaine  or  analgesic  effect  of  mor-
phine.
No other  differences  were  observed  between  groups  at
any  assessment  time.  In  this  study,  intravenous  lidocaine
infusion  during  surgery  (2  mg  kg−1 h−1)  without  initial  bolus
did  not  improve  postoperative  analgesia  or  reduce  IL-6
plasma  levels  in  patients  undergoing  open  abdominal  hys-
terectomy.
More  studies  are  needed  to  conﬁrm  these  results  and
evaluate  the  beneﬁcial  effects  of  lidocaine  in  patients
undergoing  other  types  of  surgery.  Moreover,  the  appropriate
dose,  the  onset  time,  and  the  duration  of  lidocaine  infu-
sion  required  to  reduce  the  postoperative  pain  remain  to  be
determined.
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